What are the indications for sorafenib treatment in patients with renal cell carcinoma?

被引：1
作者：
Twardowski, Przemyslaw
Figlin, Robert Alan
机构：
[1] City Hope Natl Med Ctr, Div Med Oncol & Expt Therapeut, Duarte, CA 91010 USA
[2] Beckman Res Inst, Div Med Oncol & Expt Therapeut, Duarte, CA 91010 USA
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2007年 / 4卷 / 08期
关键词：
cytokine; renal cell carcinoma; sorafenib; sunitinib;
D O I：
10.1038/ncponc0880
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：456 / 457
页数：2
相关论文
共 4 条
[1]   Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [J].
Motzer, Robert J. ;
Hutson, Thomas E. ;
Tomczak, Piotr ;
Michaelson, M. Dror ;
Bukowski, Ronald M. ;
Rixe, Olivier ;
Oudard, Stephane ;
Negrier, Sylvie ;
Szczylik, Cezary ;
Kim, Sindy T. ;
Chen, Isan ;
Bycott, Paul W. ;
Baum, Charles M. ;
Figlin, Robert A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :115-124
[2]   Sunitinib in patients with metastatic renal cell carcinoma [J].
Motzer, Robert J. ;
Rini, Brian I. ;
Bukowski, Ronald M. ;
Curti, Brendan D. ;
George, Daniel J. ;
Hudes, Gary R. ;
Redman, Bruce G. ;
Margolin, Kim A. ;
Merchan, Jaime R. ;
Wilding, George ;
Ginsberg, Michelle S. ;
Bacik, Jennifer ;
Kim, Sindy T. ;
Baum, Charles M. ;
Michaelson, M. Dror .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2516-2524
[3]  
RINI BI, 2006, J CLIN ONCOL, V24, P4522
[4]  
TWARDOWSKI P, 2006, EMERGING TARGETED TH
1